Human Applications
Veterinary Applications

DBAF202 is administered orally to newborn calves (within 24 hours of birth) to prevent cryptosporidiosis, a serious economic burden in the dairy industry. According to the USDA, Cryptosporidium occurs in nearly 90% of all dairy farms. Cryptosporidiosis is a leading cause of diarrheal disease and death in young calves. Infection occurs primarily in the first month of life through ingestion of oocysts in the environment or directly through the fecal-oral route. Calves which survive infection develop immunity providing protection to further disease. Animals with cryptosporidial disease may have impaired growth and weight gain impacting lifelong productivity. Oocysts are very resistant and difficult to remove or destroy. There are no drugs currently approved for specific treatment of cryptosporidiosis in the United States or EU. DBAFs have demonstrated efficacy in treatment of experimentally infected calves and when given as a prophylactic prior to challenge. Based on this promising efficacy data in a neonatal calf model, this product is ready for late-stage studies required for approvals.

The flow chart below shows the status of our pipeline:
19 March 2016
Preprint publication Antibody mimicry in Zika infections.
Click for details.

02 March 2016
Published by PLOS Neglected Tropical Diseases, Zika Response Group Review Paper on Countermeasure Development

Click for details.
Click here for ioGenetics immunoinformatics.